"karolinska cocktail"
Small molecule
"karolinska cocktail" is one of 44 small molecule programs targeting Morbid Obesity. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Morbid Obesity
#DrugCompanyPhaseTrials
1Lovenox
SanofiApproved
Ozempic
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Approved
Xarelto
WWim Janssens
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Tylenol
KKenvue Brands
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for "karolinska cocktail". EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- FFundacion IMIM